SCHEMBL7175145

SCHEMBL7175145

CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(=O)O

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.85
MAPT P10636 7/20 0.85
CYP3A4 P08684 6/20 0.85
RXRA P19793 5/20 0.85
RARA P10276 4/20 0.85
RARB P10826 4/20 0.85
RARG P13631 4/20 0.85
PTGS1 P23219 4/20 0.85
APP P05067 4/20 0.85
SNCA P37840 4/20 0.85
MAPK1 P28482 3/20 0.85
ALOX15 P16050 3/20 0.85
RXRB P28702 2/20 0.85
RXRG P48443 2/20 0.85
RORC P51449 2/20 0.85
ADORA3 P0DMS8 2/20 0.85
HTR2B P41595 2/20 0.85
BLM P54132 2/20 0.85
HIF1A Q16665 2/20 0.85
DRD3 P35462 2/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7162641 1.00 ALDH1A1 (0.85) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL10623339 0.99 ALDH1A1 (0.88) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL10623334 0.99 ALDH1A1 (0.88) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL17052744 0.95 ALDH1A1 (0.77) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL4821672 0.95 ALDH1A1 (0.77) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL4821667 0.95 ALDH1A1 (0.77) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL2834051 0.94 ALDH1A1 (0.84) ALDH1A1MAPTCYP3A4RXRARARA
Tretinoin SCHEMBL24982761 0.92 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Tretinoin SCHEMBL18667 0.92 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Alitretinoin SCHEMBL5331051 0.92 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10668039-B2 Methods for treatment of adenoid cystic carcinoma THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-06-02 US disclosed
US-20190192468-A1 METHODS FOR TREATMENT OF ADENOID CYSTIC CARCINOMA THE CHILDREN'S MEDICAL CENTER CORPORATION 2019-06-27 US disclosed
WO-2015143190-A1 ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2015-09-24 WO disclosed
WO-2012125724-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS BETH ISRAEL DEACONESS MEDICAL CENTER (US) 2012-09-20 WO disclosed
US-20030119715-A1 Treatment of hyperproliferative diseases VAMPEX LIMITED (GB) 2003-06-26 US disclosed
US-5723329-A POLYPEPTIDES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1998-03-03 US disclosed
US-5702914-A GENETIC ENGINEERING; BIOASSAY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1997-12-30 US disclosed